Access to GLP-1 Weight Loss Drugs in the US, Canada, Switzerland, and Germany
Kerstin Noëlle Vokinger, Emanuel Nussli, Stacie B. Dusetzina
Abstract
This Viewpoint compares use and costs of glucagon-like peptide 1 (GLP-1) receptor agonists for weight loss between the US and 3 other peer countries.
Topics & Concepts
MedicineWeight lossGlucagon-like peptide-1ExenatideGlucagon-like peptide 1 receptorInternal medicineObesityEndocrinologyDiabetes mellitusReceptorAgonistType 2 diabetesDiabetes Treatment and ManagementPharmacology and Obesity Treatment